Source: Virtual Congress 2021 – Pharmacology of airway diseases: clinical and laboratory studies



Rating:

Share or cite this content

Citations should be made in the following way:
A. Kulkarni (Mahape, Navi Mumbai, Maharashtra, 400709, , India), S. Das (Mahape, Navi Mumbai, Maharashtra, 400709, , India), S. Shelke (Mahape, Navi Mumbai, Maharashtra, 400709, , India), S. Pardeshi (Mahape, Navi Mumbai, Maharashtra, 400709, , India), M. Bajpai (Mahape, Navi Mumbai, Maharashtra, 400709, , India), V. Potdar (Mahape, Navi Mumbai, Maharashtra, 400709, , India), S. Kadam (Mahape, Navi Mumbai, Maharashtra, 400709, , India), V. Bhosale (Mahape, Navi Mumbai, Maharashtra, 400709, , India), H. Patil (Mahape, Navi Mumbai, Maharashtra, 400709, , India), D. Behera (Mahape, Navi Mumbai, Maharashtra, 400709, , India), V. Udupa (Mahape, Navi Mumbai, Maharashtra, 400709, , India), K. Vinod (Mahape, Navi Mumbai, Maharashtra, 400709, , India), C. Caracta (750, Corporate Drive, Mahwah, NJ 07430, , United States of America), P. Iyer (Mahape, Navi Mumbai, Maharashtra, 400709, , India). GRC39815-A novel inhaled ROR?t inhibitor as a potential first in class treatment option for COPD. 2128

Member's Comments

No comment yet.

Related content which might interest you: An inhaled “bifunctional” dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD Source: Eur Respir J, 52 (5) 1801675; 10.1183/13993003.01675-2018 Year: 2018 LATE-BREAKING ABSTRACT: Anti-inflammatory effect of a novel inhaled dual PDE3/4 inhibitor RPL554 in man, a unique “first-in-class” drug for the treatment of COPD & asthma Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013 Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019 A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD Source: Eur Respir J 2009; 33: 1039-1044 Year: 2009 A new combination therapeutic approach challenging the current dogma of using inhaled corticosteroids as maintenance only to control asthma Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006 A new class of bronchodilator improves lung function in COPD: a trial with GSK961081 Source: Eur Respir J 2013; 42: 972-981 Year: 2013 LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases Year: 2021 Pharmacological characterization of CHF6162, a novel long acting inhaled corticosteroid for the treatment of asthma Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017 LATE-BREAKING ABSTRACT: Novel inhaled ROR/c inhibitor for potential treatment of COPD Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 Targeting small airways in asthma: the new challenge of inhaled corticosteroid treatment Source: Eur Respir J 2008; 31: 1145-1147 Year: 2008 The novel selective PDE4 inhibitor roflumilast: early onset of efficacy in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 The effectiveness of inhaled steroids as first-line therapy in the treatment of newly detected asthma Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001 Treatment with inhaled corticosteroids (ICS) in patients with COPD: possible way of optimisation Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Highly efficient dual and triple combination therapies with no coformulation effect for treatment of COPD Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012 Absence of respiratory effects in asthmatic subjects with the If inhibitor ivabradine, a novel anti-anginal agent Source: Eur Respir J 2006; 28: Suppl. 50, 664s Year: 2006 Triple therapy versus dual bronchodilation and long-acting ß-agonists/inhaled corticosteroids in COPD: accumulating evidence from network meta-analyses Source: International Congress 2019 – Therapeutic breakthrough Year in review Year: 2019 The effect of combined β2-agonist and anticholinergic inhaled therapy in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004